Revolution in Nanobiotechnology with Cancer Detection Kit

Jul 29, 2004

Acrongenomics Inc. is pleased to introduce the revolutionary design of its nanobiotechnology product, the Neo-EpCAM(TM) cancer detection kit, which fuses molecular diagnostics with nanotechnology.

The Neo-EpCAMTM kit will be used for the detection of cancers of epithelial origin such as, lung, breast, colon, prostate, head and neck, stomach, ovary, pancreas, oesophagus, and larynx.

The Neo-EpCAM(TM) cancer detection kit can be performed on the most commonly used technological platform, the PCR (Polymerase Chain Reaction), for molecular diagnostics. The never-before-seen rapidity in molecular diagnostics will now have the advantage of increased sensitivity and specificity. The diagnostic test can be performed by personnel already trained and familiar with the PCR, and does not require additional scientific skills.

The technology dramatically reduces lab result time and labour costs by up to 75%, thereby substantially increasing productivity to all diagnostic centers and laboratories. As a result, this significant improvement offers patients better service and benefits.

Progress on Neo-EpCAMTM evaluation studies has brought Acrongenomics one step closer to the development of a commercial product.

Important Information About Forward-Looking Statements

All statements in this news release, that are other than statements of historical facts, are forward-looking statements, which contain our current expectations about our future results. Forward-looking statements involve numerous risks and uncertainties. We have attempted to identify any forward-looking statements by using words such as "anticipates", "believes", "could", "expects", "intends", "may", "should" and other similar expressions. Although we believe that the expectations reflected in all of our forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.

A number of factors may affect our future results and may cause those results to differ materially from those indicated in any forward-looking statements made by us or on our behalf. Such factors include our limited operating history; our need for significant capital to finance internal growth as well as strategic acquisitions; our ability to attract and retain key employees and strategic partners; our ability to achieve and maintain profitability; fluctuations in the trading price and volume of our stock; competition from other providers of similar products and services; and other unanticipated future events and conditions.

For further information concerning risks and uncertainties that may affect our future results, please review the disclosures contained in our latest filings with the SEC, including our most recent annual report on Form 10-KSB, and subsequent quarterly reports on Form 10-QSB. Other than as required by federal securities laws, we undertake no obligation to publicly update or revise any of our forward-looking statements, whether as a result of changed circumstances, new information, future events, or for any other reason occurring after the date of this news release.

Source: Acrongenomics Inc.

Explore further: Research aims to improve rechargeable batteries by focusing on graphene oxide paper

add to favorites email to friend print save as pdf

Related Stories

Underfire Uber ramps up rider safety

2 hours ago

Uber is ramping up driver background checks and other security measures worldwide after the smartphone-focused car-sharing service was banned in New Delhi following the alleged rape of a passenger.

US probe links NKorea to Sony hacking

2 hours ago

A U.S. official says federal investigators have now connected the Sony Pictures Entertainment Inc. hacking to North Korea and are expected to make an announcement in the near future.

New York state bans fracking

2 hours ago

Governor Andrew Cuomo said Wednesday he would ban hydraulic fracking in New York State, citing health concerns about the controversial oil and gas drilling technique.

Sony cancels NKorea parody film release after threats

2 hours ago

Hollywood studio Sony Pictures on Wednesday abruptly canceled the December 25 release date of "The Interview," a parody film which has angered North Korea and triggered chilling threats from hackers.

Recommended for you

Gold nanorods target cancer cells

Dec 18, 2014

Using tiny gold nanorods, researchers at Swinburne University of Technology have demonstrated a potential breakthrough in cancer therapy.

Chemically driven micro- and nanomotors

Dec 17, 2014

At least since the movie "The Fantastic Voyage" in 1966, in which a submarine is shrunk down and injected into the blood stream of a human, people have been toying with the idea of sending tiny "micromachines" ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.